Core Laboratories (NYSE:CLB) PT Raised to $18.00

Core Laboratories (NYSE:CLB - Get Free Report) had its price objective upped by stock analysts at Stifel Nicolaus from $17.00 to $18.00 in a report released on Friday, Benzinga reports. The brokerage presently has a "hold" rating on the oil and gas company's stock. Stifel Nicolaus' price target suggests a potential upside of 6.26% from the company's current price.

Several other equities analysts have also recently issued reports on the company. Bank of America lowered their price objective on Core Laboratories from $17.00 to $16.00 and set an "underperform" rating on the stock in a research report on Monday, April 15th. StockNews.com raised Core Laboratories from a "sell" rating to a "hold" rating in a research report on Saturday, January 20th. Two analysts have rated the stock with a sell rating and three have assigned a hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $18.75.

Core Laboratories Stock Down 0.8 %

Shares of Core Laboratories stock traded down $0.13 during midday trading on Friday, hitting $16.94. The company had a trading volume of 522,902 shares, compared to its average volume of 468,506. The stock has a market capitalization of $793.81 million, a P/E ratio of 19.55, a P/E/G ratio of 0.94 and a beta of 2.40. Core Laboratories has a 52-week low of $13.82 and a 52-week high of $27.94. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.72 and a current ratio of 2.53. The company has a 50 day moving average of $16.29 and a 200 day moving average of $17.66.

Core Laboratories (NYSE:CLB - Get Free Report) last released its quarterly earnings data on Wednesday, April 24th. The oil and gas company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.02. The business had revenue of $129.64 million for the quarter, compared to analysts' expectations of $124.47 million. Core Laboratories had a return on equity of 15.90% and a net margin of 8.18%. On average, equities analysts predict that Core Laboratories will post 0.8 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Core Laboratories

Institutional investors have recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC bought a new position in Core Laboratories in the 3rd quarter worth $31,000. GAMMA Investing LLC bought a new position in Core Laboratories in the 4th quarter worth $48,000. Quadrant Capital Group LLC raised its holdings in Core Laboratories by 84.0% in the 4th quarter. Quadrant Capital Group LLC now owns 3,370 shares of the oil and gas company's stock worth $60,000 after purchasing an additional 1,538 shares during the period. CWM LLC raised its holdings in Core Laboratories by 1,178.6% in the 1st quarter. CWM LLC now owns 3,580 shares of the oil and gas company's stock worth $61,000 after purchasing an additional 3,300 shares during the period. Finally, Lindbrook Capital LLC raised its holdings in Core Laboratories by 19.7% in the 1st quarter. Lindbrook Capital LLC now owns 3,713 shares of the oil and gas company's stock worth $63,000 after purchasing an additional 612 shares during the period. 97.81% of the stock is owned by institutional investors.

Core Laboratories Company Profile

Core Laboratories Inc provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs.